Emavusertib (Synonyms: CA-4948) |
| Catalog No.GC52002 |
Emavusertib(CA-4948)은 항종양 활성이 있는 강력한 IRAK4/FLT3 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1801344-14-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Emavusertib is an inhibitor of IL-1 receptor-associated kinase 4 (IRAK4; IC50 = 31.7 nM).1 It is selective for IRAK4 over FMS-related tyrosine kinase 3 (FLT3), cyclin-dependent kinase 2 (Cdk2), Aurora A kinase, glycogen synthase kinase 3β (GSK3β), and muscle-associated receptor tyrosine kinase (MUSK) at 1 µM. Emavusertib inhibits IL-6 release mediated by toll-like receptor 2 (TLR2), TLR5, or IL-1 receptor (IL-1R) in isolated human whole blood (IC50s = 989, 696, and 1,375 nM, respectively). In vivo, emavusertib (25-200 mg/kg) reduces tumor volume in an OCI-Ly3 diffuse large B cell lymphoma (DLBCL) mouse xenograft model.
1.Gummadi, V.R., Boruah, A., Ainan, B.R., et al.Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignanciesACS Med. Chem. Lett.11(12)2374-2381(2020)
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *